Comparing Exscientia (NASDAQ:EXAI) and IN8bio (NASDAQ:INAB)

Exscientia (NASDAQ:EXAI) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Institutional & Insider Ownership

41.6% of Exscientia shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 16.4% of Exscientia shares are owned by company insiders. Comparatively, 33.0% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Exscientia and IN8bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Exscientia	-737.10%	-36.44%	-26.39%
IN8bio	N/A	-147.67%	-105.00%

Volatility & Risk

Exscientia has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, IN8bio has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500.

Valuation & Earnings

This table compares Exscientia and IN8bio’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exscientia	$20.08 million	34.44	-$181.56 million	($1.48)	-3.86
IN8bio	N/A	N/A	-$30.01 million	($1.01)	-1.17

IN8bio has lower revenue, but higher earnings than Exscientia. Exscientia is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Exscientia and IN8bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exscientia	0	2	2	0	2.50
IN8bio	0	0	3	0	3.00

Exscientia presently has a consensus price target of $9.75, suggesting a potential upside of 70.45%. IN8bio has a consensus price target of $9.83, suggesting a potential upside of 733.33%. Given IN8bio’s stronger consensus rating and higher possible upside, analysts clearly believe IN8bio is more favorable than Exscientia.

Summary

IN8bio beats Exscientia on 9 of the 13 factors compared between the two stocks.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

About IN8bio

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.